BackgroundCheck.run
Search For

Peter Andrew Mckenney, 57173 Stowaway Rd, Cedar Bonnet Island, NJ 08050

Peter Mckenney Phones & Addresses

173 Stowaway Rd, Manahawkin, NJ 08050    609-9943894    856-9943894   

Stafford Township, NJ   

Adams, NY   

Lorraine, NY   

29 Tinton Falls Rd, Farmingdale, NJ 07727    908-9075448   

Eatontown, NJ   

Joint Base Lewis Mcchord, WA   

Jefferson, NY   

Stafford Twp, NJ   

29 Tinton Falls Rd, Farmingdale, NJ 07727   

Mentions for Peter Andrew Mckenney

Peter Mckenney resumes & CV records

Resumes

Peter Mckenney Photo 26

Peter Mckenney

Peter Mckenney Photo 27

Freelance Writer

Location:
Manahawkin, NJ
Work:

Freelance Writer
Peter Mckenney Photo 28

Peter Mckenney

Peter Mckenney Photo 29

Peter Mckenney

Publications & IP owners

Us Patents

Methods And Compositions For Reducing Vancomycin-Resistant Enterococci Infection Or Colonization

US Patent:
2021000, Jan 7, 2021
Filed:
May 8, 2020
Appl. No.:
16/870634
Inventors:
- New York NY, US
Peter McKenney - New York NY, US
Silvia Caballero - Cambridge MA, US
Assignee:
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
A61K 35/741
A61K 35/74
C12N 1/20
A61P 31/04
A61K 9/00
Abstract:
The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria and/or the bacteria contribute substantially to resistance against vancomycin-resistant infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of

Lantibiotics, Lantibiotic-Producing Bacteria, Compositions And Methods Of Production And Use Thereof

US Patent:
2020009, Mar 26, 2020
Filed:
Oct 21, 2019
Appl. No.:
16/659199
Inventors:
- NEW YORK NY, US
SOHN KIM - NEW YORK NY, US
PETER MCKENNEY - NEW YORK NY, US
SILVIA CABALLERO - CAMBRIDGE MA, US
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER - NEW YORK NY
International Classification:
A61K 38/12
C12N 1/20
A61P 31/04
A61K 38/44
C12P 21/00
Abstract:
The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

Methods And Compositions For Reducing Clostridium Difficile Infection

US Patent:
2019038, Dec 19, 2019
Filed:
Jul 26, 2019
Appl. No.:
16/523414
Inventors:
- New York NY, US
Charlie Buffie - New York NY, US
Peter McKenney - New York NY, US
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY
International Classification:
A61K 35/74
C12Q 1/26
A61K 38/44
A61K 45/06
C12N 9/04
Abstract:
The present invention relates to methods and compositions for reducing the risk and severity of infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium , contributes substantially to resistance against infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

Methods And Compositions For Reducing Vancomycin-Resistant Enterococci Infection Or Colonization

US Patent:
2018025, Sep 13, 2018
Filed:
May 22, 2018
Appl. No.:
15/986369
Inventors:
- New York NY, US
Peter McKenney - New York NY, US
Silvia Caballero - Cambridge MA, US
International Classification:
A61K 35/741
A61P 31/04
A61K 9/00
Abstract:
The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria and/or the bacteria contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of

Methods And Compositions For Reducing Clostridium Difficile Infection

US Patent:
2017008, Mar 30, 2017
Filed:
May 19, 2015
Appl. No.:
15/312610
Inventors:
- New York NY, US
Charlie Buffie - New York NY, US
Peter McKenney - New York NY, US
International Classification:
A61K 35/74
C12Q 1/26
C12N 9/04
A61K 38/44
A61K 45/06
Abstract:
The present invention relates to methods and compositions for reducing the risk and severity of infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the contributes substantially to resistance against infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.